Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.

Phase 1 data support continued investigation of roginolisib in advanced cancers, including metastatic uveal melanoma.

The NCCN update adds locally advanced CSCC to the category 2A listing that cosibelimab received for metastatic disease in 2025.

The CHMP opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.

New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.